HRP20170662T1 - Nedirnute ministanice, izvedene iz bakterija, koje sadrže regulatornu rnk - Google Patents
Nedirnute ministanice, izvedene iz bakterija, koje sadrže regulatornu rnk Download PDFInfo
- Publication number
- HRP20170662T1 HRP20170662T1 HRP20170662TT HRP20170662T HRP20170662T1 HR P20170662 T1 HRP20170662 T1 HR P20170662T1 HR P20170662T T HRP20170662T T HR P20170662TT HR P20170662 T HRP20170662 T HR P20170662T HR P20170662 T1 HRP20170662 T1 HR P20170662T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition
- minicells
- regulatory
- rnas
- rna
- Prior art date
Links
- 230000001105 regulatory effect Effects 0.000 title claims 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 26
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 11
- 241000894006 Bacteria Species 0.000 claims 4
- 210000004962 mammalian cell Anatomy 0.000 claims 4
- 102000053642 Catalytic RNA Human genes 0.000 claims 3
- 108090000994 Catalytic RNA Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 238000011065 in-situ storage Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 108091092562 ribozyme Proteins 0.000 claims 3
- 101001030069 Homo sapiens Major vault protein Proteins 0.000 claims 2
- 102100038884 Major vault protein Human genes 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000008774 maternal effect Effects 0.000 claims 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 claims 1
- 206010059866 Drug resistance Diseases 0.000 claims 1
- 102100030943 Glutathione S-transferase P Human genes 0.000 claims 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 claims 1
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 claims 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- 102000002258 X-ray Repair Cross Complementing Protein 1 Human genes 0.000 claims 1
- 108010000443 X-ray Repair Cross Complementing Protein 1 Proteins 0.000 claims 1
- 208000036815 beta tubulin Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000000805 cytoplasm Anatomy 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 108090000743 multidrug resistance protein 3 Proteins 0.000 claims 1
- 102000004233 multidrug resistance protein 3 Human genes 0.000 claims 1
- -1 nuclear factor kappa Proteins 0.000 claims 1
- 230000000242 pagocytic effect Effects 0.000 claims 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11021—Polo kinase (2.7.11.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Claims (15)
1. Sastav sadrži
a. skupina nedirnutih ministanica, izvedenih iz bakterija, gdje svaka mnistanica u pluralitetu sadrži regulatornu RNK koja je sadržana u ministanici
b. farmaceutski prihvatljiv nositelj istih
naznačeno time da (i) regulatorna RNK je izabrana iz grupe koja se sastoji od negativnih jednolančanih RNK, ribozima i RNK-mamaca, (ii) u ministanicama nedostaje konstrukt in situ ekspresije regulatornih RNK, te (iii) pluralitet obuhvaća terapijski efektivnu količinu regultornih RNA.
2. Sastav zahtjeva 1, time naznačeno da regulatorna RNK nije kemijski modificirana.
3. Sastav zahtjeva 1, time naznačeno da regulatorna RNK posebno ometa ekspresiju proteina koji pridonosi stvaranju otpornosti na ljekove.
4. Sastav zahtjeva 3, time naznačeno da je protein P-glikoprotein, MDR-2 ili MDR-3.
5. Sastav zahtjeva 3, time naznačeno da je protein MRP2, BCR-ABL, STI-571 povezan sa stvaranjem otpornosti, LRP (lung resistance related protein), ciklooksigenaza-2, nuklearni čimbenik kapa, XRCC1, ERCC1, GSTP1, mutant β-tubulin ili čimbenik rasta.
6. Sastav zahtjeva 1, nadalje sadrži i bispecifičan ligan.
7. Sastav zahtjeva 6, naznačeno time da bispecifični ligand se sastoji od prvog kraka koji je nositelj posebnosti za strukturu površine ministanica, te drugi krak koji je nositelj posebnosti za receptore površine nefagocitnih stanica sisavaca.
8. Sastav zahtjeva 7, naznačeno time da je receptor površine stanica sisavaca sposoban pokrenuti receptorima posredovanu endocitozu ministanica.
9. Sastav zahtjeva 1, naznačeno time da sastav sadrži manje od oko 1 kontaminirane bakterijske stanice majke na 10¹ ministanica.
10. Sastav zahtjeva 1, naznačeno time da sastav sadrži manje od oko 1 kontaminirane bakterijske stanice majke na 10¹¹ ministanica.
11. Sastav zahtjeva 1, naznačeno time da regulatorna RNK je negativna jednolančana RNA.
12. Sastav korišten u liječenju raka, naznačeno time da sastav obuhvaća pluralitet nedirnutih ministanica izvedenih iz bakterija u faramceutski prihvatljivom nositelju, a svaka ministanica puliraliteta sadrži regulatornu RNK naznačeno time da:
a. regulatorna RNK je izabrana iz grupe koja se sastoji od negativnih jednolančanih RNA, ribozima i RNK-mamaca;
b. u ministanicama nedostaje konstrukt in situ ekspresije regulatorne RNK, te
c. pularitet ministanica koje sadrže terapeutski zadovoljavajuću količinu regulatornih RNK.
13. Metoda dobivanja regulatornih RNA sastoji se od sljedećih koraka:
a. snadbjevanje pulraliteta nedirnutih ministanica izvedenih iz bakterija u farmaceutski prihvatljivom nositelju, a svaka ministanica puliraliteta sadrži regulatornu RNK; i
b. dovođenje ministanica pluraliteta u kontakt sa stanicama sisavaca in vitro tako da stanica sisavaca progutaju ministanice pluraliteta, te se time regulatorna RNK otpušta u citoplazmu ciljanih stanica,
naznačeno time da (i) je regulatorna RNA izabrana iz grupe koje sadrži negativne jednolančane RNK, ribozime i RNA-mamce, (ii) u ministanicama nedostaje konstrukt in situ ekspresije regulatorne RNK, te (iii) pluralitet sadrži terapetski zadovoljavajuću dozu regulatornih RNK.
14. Metoda formulacije sastava zahtjeva 1, koji obuhvaća koinkubaciju pluraliteta nedirnutih ministanica izvedenih iz bakterija i regulatornih RNK u puferu.
15. Metoda zahtjeva 14, naznačeno time da spomenuta regulatorna RNK je negativna jednolančana RNA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90907407P | 2007-03-30 | 2007-03-30 | |
| EP15150129.3A EP2865755B1 (en) | 2007-03-30 | 2008-03-26 | Bacterially derived, intact minicells encompassing regulatory RNA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170662T1 true HRP20170662T1 (hr) | 2017-07-14 |
Family
ID=40386454
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150328TT HRP20150328T1 (hr) | 2007-03-30 | 2015-03-23 | Bakterijski dobivene, intaktne mini-stanice koje obuhvaä†aju funkcionalnu nukleinsku kiselinu, bez plazmida, za in vivo dopremu do stanica sisavaca |
| HRP20170662TT HRP20170662T1 (hr) | 2007-03-30 | 2017-05-02 | Nedirnute ministanice, izvedene iz bakterija, koje sadrže regulatornu rnk |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150328TT HRP20150328T1 (hr) | 2007-03-30 | 2015-03-23 | Bakterijski dobivene, intaktne mini-stanice koje obuhvaä†aju funkcionalnu nukleinsku kiselinu, bez plazmida, za in vivo dopremu do stanica sisavaca |
Country Status (18)
| Country | Link |
|---|---|
| EP (5) | EP2145002B1 (hr) |
| JP (1) | JP5167338B2 (hr) |
| CN (2) | CN101715489B (hr) |
| AU (1) | AU2008291833B2 (hr) |
| CA (3) | CA2933978C (hr) |
| CY (1) | CY1119031T1 (hr) |
| DK (2) | DK2145002T3 (hr) |
| ES (2) | ES2534435T3 (hr) |
| HK (2) | HK1138326A1 (hr) |
| HR (2) | HRP20150328T1 (hr) |
| LT (1) | LT2865755T (hr) |
| MX (1) | MX2009010411A (hr) |
| NZ (1) | NZ580487A (hr) |
| PL (2) | PL2865755T3 (hr) |
| PT (2) | PT2145002E (hr) |
| SG (2) | SG10201507969PA (hr) |
| SI (2) | SI2145002T1 (hr) |
| WO (1) | WO2009027830A2 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4965447B2 (ja) | 2004-08-26 | 2012-07-04 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 細菌由来のインタクトなミニセルを介した哺乳動物細胞への機能性核酸の送達 |
| SG10201507969PA (en) * | 2007-03-30 | 2015-10-29 | Engeneic Molecular Delivery Pty Ltd | Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells |
| DE102009017908A1 (de) * | 2009-04-17 | 2010-10-21 | Kist-Europe Forschungsgesellschaft Mbh | Vektor für den Transport von mikrobiologischen Organismen zu Krankheitsherden |
| EP2478101A1 (en) * | 2009-09-16 | 2012-07-25 | Stichting Het Nederlands Kanker Instituut | Fra-1 target genes as drug targets for treating cancer |
| MX359410B (es) | 2011-12-13 | 2018-09-27 | Engeneic Molecular Delivery Pty Ltd | Minicélulas intactas derivadas bacterialmente para suministro de agentes terapéuticos a tumores cerebrales. |
| US9006200B2 (en) * | 2013-03-13 | 2015-04-14 | Asbestos Diseases Research Foundation | MicroRNA-based approach to treating malignant pleural mesothelioma |
| TWI737576B (zh) | 2013-10-04 | 2021-09-01 | 澳大利亞商安珍尼Ｉｃ分子輸送私人有限公司 | 使用藥物裝載之雙特異性配位體標靶的微型細胞與干擾素-γ的組合式腫瘤治療 |
| CA2963218C (en) * | 2014-10-03 | 2023-10-24 | Engeneic Molecular Delivery Pty Ltd | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
| SG11201902940RA (en) | 2016-10-06 | 2019-05-30 | Engeneic Molecular Delivery Pty Ltd | Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same |
| BR112019022539A2 (pt) | 2017-04-28 | 2020-06-16 | Agrospheres, Inc. | Composições e métodos para o encapsulamento e entrega escalonável de agorquímicos |
| EP3615082A4 (en) | 2017-04-28 | 2021-05-26 | Agrospheres, Inc. | COMPOSITIONS AND PROCEDURES FOR ENZYMIMMOBILIZATION |
| EP3688168A4 (en) * | 2017-09-25 | 2021-07-14 | Agrospheres, Inc. | COMPOSITIONS AND PROCESSES FOR THE PRODUCTION AND ADVANCED ADMINISTRATION OF ORGANIC PRODUCTS |
| CN112689511A (zh) | 2018-07-23 | 2021-04-20 | 安吉尼科分子传输公司 | 包含细菌源微细胞的组合物及其使用方法 |
| EP4061802A4 (en) * | 2019-12-23 | 2024-01-24 | Agrospheres Inc | COMPOSITIONS AND METHODS FOR IMPROVED ABSORPTION OF ACTIVE INGREDIENTS FOR ANIMAL HEALTH AND NUTRITION |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4496778A (en) | 1983-10-03 | 1985-01-29 | Exxon Research & Engineering Co. | Process for the hydroxylation of olefins using molecular oxygen, an osmium containing catalyst, a copper Co-catalyst, and an aromatic amine based promoter |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
| MXPA01011429A (es) | 1999-05-11 | 2003-09-10 | Ortho Mcneil Pharm Inc | Modelado farmacocinetico y farmacodinamico de administracion de eritropoyetina. |
| JP4458846B2 (ja) | 2001-10-15 | 2010-04-28 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | ｉｎｖｉｔｒｏおよびｉｎｖｉｖｏにおけるＤＮＡ導入および遺伝子療法のためのベクターとしての完全なミニ細胞 |
| US20040053289A1 (en) * | 2002-09-09 | 2004-03-18 | The Regents Of The University Of California | Short interfering nucleic acid hybrids and methods thereof |
| US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
| DE602004031870D1 (de) | 2003-12-09 | 2011-04-28 | Engeneic Molecular Delivery Pty Ltd | Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellen |
| SI1718338T1 (sl) | 2004-02-02 | 2015-09-30 | Engeneic Molecular Delivery Pty Ltd. | Sestavki in metode za ciljno usmerjeno in vitro in in vivo dostavo zdravila v celice sesalcev preko bakterijsko pridobljenih intaktnih minicelic |
| JP4965447B2 (ja) * | 2004-08-26 | 2012-07-04 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 細菌由来のインタクトなミニセルを介した哺乳動物細胞への機能性核酸の送達 |
| SG10201507969PA (en) * | 2007-03-30 | 2015-10-29 | Engeneic Molecular Delivery Pty Ltd | Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells |
-
2008
- 2008-03-26 SG SG10201507969PA patent/SG10201507969PA/en unknown
- 2008-03-26 EP EP08828079.7A patent/EP2145002B1/en active Active
- 2008-03-26 EP EP15150129.3A patent/EP2865755B1/en active Active
- 2008-03-26 JP JP2010500390A patent/JP5167338B2/ja active Active
- 2008-03-26 CN CN200880018076.XA patent/CN101715489B/zh active Active
- 2008-03-26 SG SG10201804257RA patent/SG10201804257RA/en unknown
- 2008-03-26 PT PT88280797T patent/PT2145002E/pt unknown
- 2008-03-26 NZ NZ580487A patent/NZ580487A/en unknown
- 2008-03-26 SI SI200831411T patent/SI2145002T1/sl unknown
- 2008-03-26 AU AU2008291833A patent/AU2008291833B2/en active Active
- 2008-03-26 CA CA2933978A patent/CA2933978C/en active Active
- 2008-03-26 DK DK08828079.7T patent/DK2145002T3/en active
- 2008-03-26 CN CN201610277472.0A patent/CN105854029B/zh active Active
- 2008-03-26 DK DK15150129.3T patent/DK2865755T3/en active
- 2008-03-26 PL PL15150129T patent/PL2865755T3/pl unknown
- 2008-03-26 PL PL08828079T patent/PL2145002T3/pl unknown
- 2008-03-26 MX MX2009010411A patent/MX2009010411A/es active IP Right Grant
- 2008-03-26 LT LTEP15150129.3T patent/LT2865755T/lt unknown
- 2008-03-26 WO PCT/IB2008/002984 patent/WO2009027830A2/en active Application Filing
- 2008-03-26 SI SI200831798A patent/SI2865755T1/sl unknown
- 2008-03-26 ES ES08828079.7T patent/ES2534435T3/es active Active
- 2008-03-26 ES ES15150129.3T patent/ES2626179T3/es active Active
- 2008-03-26 CA CA2844647A patent/CA2844647C/en active Active
- 2008-03-26 EP EP17153863.0A patent/EP3205724B1/en active Active
- 2008-03-26 CA CA2682704A patent/CA2682704C/en active Active
- 2008-03-26 EP EP19172998.7A patent/EP3564372A1/en active Pending
- 2008-03-26 PT PT151501293T patent/PT2865755T/pt unknown
- 2008-03-26 EP EP12178465.6A patent/EP2532746A3/en not_active Withdrawn
-
2010
- 2010-05-25 HK HK10105130.8A patent/HK1138326A1/xx unknown
-
2015
- 2015-03-23 HR HRP20150328TT patent/HRP20150328T1/hr unknown
- 2015-10-26 HK HK15110506.9A patent/HK1209786A1/xx unknown
-
2017
- 2017-05-02 CY CY20171100476T patent/CY1119031T1/el unknown
- 2017-05-02 HR HRP20170662TT patent/HRP20170662T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170662T1 (hr) | Nedirnute ministanice, izvedene iz bakterija, koje sadrže regulatornu rnk | |
| Agliano et al. | The challenge of targeting cancer stem cells to halt metastasis | |
| Carranza et al. | New insights regarding the biology of Giardia lamblia | |
| CN107083385A (zh) | 产热的miRNA调节剂 | |
| Uz et al. | Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer | |
| JP2010523487A5 (hr) | ||
| McCarthy et al. | In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer | |
| Hsu et al. | Substrate-dependent modulation of 3D spheroid morphology self-assembled in mesenchymal stem cell-endothelial progenitor cell coculture | |
| Gunawardana et al. | Microbial biofilms on the surface of intravaginal rings worn in non-human primates | |
| JP2020524149A5 (hr) | ||
| Khan et al. | Calcium release-activated calcium (CRAC) channel inhibition suppresses pancreatic ductal adenocarcinoma cell proliferation and patient-derived tumor growth | |
| Kudoh et al. | Bag1 proteins regulate growth and survival of ZR-75-1 human breast cancer cells | |
| JP2016518129A (ja) | 細胞ベースの薬物スクリーニングアッセイの方法及びその使用 | |
| Wasylnka et al. | Role for myosin II in regulating positioning of Salmonella-containing vacuoles and intracellular replication | |
| Kennedy et al. | Microvascular experimentation in the chick chorioallantoic membrane as a model for screening angiogenic agents including from gene-modified cells | |
| Ding et al. | Three‐dimensional tissue culture model of human breast cancer for the evaluation of multidrug resistance | |
| Abouzeid et al. | The role of cell cycle in the efficiency and activity of cancer nanomedicines | |
| Miserocchi et al. | Precision medicine in head and neck cancers: genomic and preclinical approaches | |
| Morad et al. | Short-chain ceramides depress integrin cell surface expression and function in colorectal cancer cells | |
| Bujdáková et al. | Participation of the Candida albicans surface antigen in adhesion, the first phase of biofilm development | |
| WO2005067632A3 (en) | Lipid compositions and use thereof | |
| Ahmadzadeh et al. | Regulatory effect of chemokines in bone marrow niche | |
| Liu et al. | Recapitulating and deciphering tumor microenvironment by using 3D printed plastic brick–like microfluidic cell patterning | |
| Chen et al. | Effects of rhynchophylline and isorhynchophylline on nitric oxide and endothelin-1 secretion from RIMECs induced by Listeriolysin O in vitro | |
| Chaves-Almagro et al. | Upregulated apelin signaling in pancreatic cancer activates oncogenic signaling pathways to promote tumor development |